Search Results - "Gass, Margery L.S."

Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile by Lobo, Rogerio A., M.D, Pinkerton, JoAnn V., M.D, Gass, Margery L.S., M.D, Dorin, Maxine H., M.D, Ronkin, Sheila, M.D, Pickar, James H., M.D, Constantine, Ginger, M.D

“…Objective To evaluate the effects of a tissue-selective estrogen complex (TSEC) composed of bazedoxifene/conjugated estrogens (BZA/CE) on menopausal symptoms,…”
Get full text

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society by Portman, David J, Gass, Margery L.S

“…BACKGROUNDIn 2012, the Board of Directors of the International Society for the Study of Women’s Sexual Health (ISSWSH) and the Board of Trustees of The North…”
Get full text

Ages at menarche and menopause and reproductive lifespan as predictors of exceptional longevity in women: the Womenʼs Health Initiative by Shadyab, Aladdin H, Macera, Caroline A, Shaffer, Richard A, Jain, Sonia, Gallo, Linda C, Gass, Margery L.S, Waring, Molly E, Stefanick, Marcia L, LaCroix, Andrea Z

“…OBJECTIVE:The aim of the present study was to investigate associations between reproductive factors and survival to age 90 years. METHODS:This was a…”
Get full text

Genitourinary Syndrome of Menopause: New Terminology for Vulvovaginal Atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society by Portman, David J., Gass, Margery L.S., Vulvovaginal Atrophy Terminology Consensus Conference Panel

“…The terminology for the genitourinary tract symptoms related to menopause was vulvovaginal atrophy, which does not accurately describe the symptoms nor is a…”
Get full text

Use of compounded hormone therapy in the United States: report of The North American Menopause Society Survey by Gass, Margery L.S, Stuenkel, Cynthia A, Utian, Wulf H, LaCroix, Andrea, Liu, James H, Shifren, Jan L

“…OBJECTIVE:A national survey was conducted to determine the extent of use of compounded hormone therapy (C-HT) and to characterize the differences between C-HT…”
Get full text

Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society by Manson, JoAnn E, Ames, Jeffrey M, Shapiro, Marla, Gass, Margery L.S, Shifren, Jan L, Stuenkel, Cynthia A, Pinkerton, JoAnn V, Kaunitz, Andrew M, Pace, Diane T, Kagan, Risa, Schnatz, Peter F, Kingsberg, Sheryl A, Liu, James H, Joffe, Hadine, Richard-Davis, Gloria, Goldstein, Steven R, Schiff, Isaac, Utian, Wulf H

Get full text

Why the product labeling for low-dose vaginal estrogen should be changed by Manson, JoAnn E, Goldstein, Steven R, Kagan, Risa, Kaunitz, Andrew M, Liu, James H, Pinkerton, JoAnn V, Rebar, Robert W, Schnatz, Peter F, Shifren, Jan L, Stuenkel, Cynthia A, Gass, Margery L.S, Utian, Wulf H

Get full text

Effect of Calcium plus Vitamin D on Risk for Invasive Cancer: Results of the Women's Health Initiative (WHI) Calcium Plus Vitamin D Randomized Clinical Trial by Brunner, Robert L, Wactawski-Wende, Jean, Caan, Bette J, Cochrane, Barbara B, Chlebowski, Rowan T, Gass, Margery L. S, Jacobs, Elizabeth T, LaCroix, Andrea Z, Lane, Dorothy, Larson, Joseph, Margolis, Karen L, Millen, Amy E, Sarto, Gloria E, Vitolins, Mara Z, Wallace, Robert B

“…In the Women's Health Initiative (WHI) trial of calcium plus vitamin D (CaD), we examined the treatment effect on incidence and mortality for all invasive…”
Get full text

A tribute to Isaac Schiff, MD, Editor-in-Chief by Utian, Wulf H, Gass, Margery L.S

Get full text

NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older by Gass, Margery L.S, Maki, Pauline M, Shifren, Jan L, Schnatz, Peter F, Kaunitz, Andrew M, Shapiro, Marla, Sievert, Lynnette Leidy

Get full text

The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety by Stovall, Dale W., Utian, Wulf H., Gass, Margery L.S., Qu, Yongming, Muram, David, Wong, Mayme, Plouffe, Leo

“…OBJECTIVE:To compare effects of 52 weeks' treatment with either raloxifene 60 mg/day alone (RLX) or in combination with 17β-estradiol 1 mg/day (RLX + E) on…”
Get full text

A decade after the Women's Health Initiative—the experts do agree by Stuenkel, Cynthia A., M.D., N.C.M.P, Gass, Margery L.S., M.D., N.C.M.P, Manson, JoAnn E., M.D., Dr.PH., N.C.M.P, Lobo, Rogerio A., M.D, Pal, Lubna, M.B.B.S., M.R.C.O.G., M.Sc., N.C.M.P, Rebar, Robert W., M.D, Hall, Janet E., M.D

Get full text

The North American Menopause Society at 25 years: celebrating our history and looking to the future by Utian, Wulf H, Schiff, Isaac, Kronenberg, Fredi, Shifren, Jan L, Gass, Margery L.S

Get full text

Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials by Chlebowski, Rowan T, Anderson, Garnet L, Aragaki, Aaron K, Manson, JoAnn E, Stefanick, Marcia L, Pan, Kathy, Barrington, Wendy, Kuller, Lewis H, Simon, Michael S, Lane, Dorothy, Johnson, Karen C, Rohan, Thomas E, Gass, Margery L. S, Cauley, Jane A, Paskett, Electra D, Sattari, Maryam, Prentice, Ross L

“…IMPORTANCE: The influence of menopausal hormone therapy on breast cancer remains unsettled with discordant findings from observational studies and randomized…”
Get full text

The 2012 Hormone Therapy Position Statement of The North American Menopause Society

“…OBJECTIVEThis position statement aimed to update the evidence-based position statement published by The North American Menopause Society (NAMS) in 2010…”
Get full text

Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society

“…OBJECTIVE:To update and expand The North American Menopause Societyʼs evidence-based position on nonhormonal management of menopause-associated vasomotor…”
Get full text

The North American Menopause Society Recommendations for Clinical Care of Midlife Women by Shifren, Jan L, Gass, Margery L.S

Get full text

Maternal Age at Childbirth and Parity as Predictors of Longevity Among Women in the United States: The Women's Health Initiative by Shadyab, Aladdin H, Gass, Margery L S, Stefanick, Marcia L, Waring, Molly E, Macera, Caroline A, Gallo, Linda C, Shaffer, Richard A, Jain, Sonia, LaCroix, Andrea Z

“…To examine associations of maternal age at childbirth and parity with survival to age 90 years (longevity). We performed a prospective study among a…”
Get full text

Abstract GS5-00: Long-term influence of estrogen plus progestin and estrogen alone use on breast cancer incidence: The Women's Health Initiative randomized trials by Chlebowski, Rowan T, Anderson, Garnet L, Aragaki, Aaron K, Manson, JoAnn E, Stefanick, Marcia, Pan, Kathy, Barrington, Wendy, Kuller, Lewis H, Simon, Michael S., Lane, Dorothy, Johnson, Karen C, Rohan, Thomas E., Gass, Margery L.S., Cauley, Jane A, Paskett, Electra D., Sattari, Maryam, Prentice, Ross L

“…Abstract Background: Breast cancer outcomes from the Women’s Health Initiative (WHI) Estrogen plus Progestin and Estrogen-alone trials have been reported but…”
Get full text

Associations of Hearing Loss and Menopausal Hormone Therapy With Change in Global Cognition and Incident Cognitive Impairment Among Postmenopausal Women by Armstrong, Nicole M, Espeland, Mark A, Chen, Jiu-Chiuan, Masaki, Kamal, Wactawski-Wende, Jean, Li, Wenjun, Gass, Margery L S, Stefanick, Marcia L, Manson, JoAnn E, Deal, Jennifer A, Rapp, Stephen R, Lin, Frank R, Resnick, Susan M

“…Abstract Background Hearing loss (HL) and menopausal hormone therapy (conjugated equine estrogens [CEE] and/or medroxyprogesterone acetate [MPA]) are…”
Get full text